158 related articles for article (PubMed ID: 30256698)
1. In silico screening for identification of fatty acid synthase inhibitors and evaluation of their antiproliferative activity using human cancer cell lines.
Nisthul A A; Retnakumari AP; A S; Anto RJ; Sadasivan C
J Recept Signal Transduct Res; 2018 Aug; 38(4):335-341. PubMed ID: 30256698
[TBL] [Abstract][Full Text] [Related]
2. Pyridine derivatives as anticancer lead compounds with Fatty Acid Synthase as the target: An in silico-guided in vitro study.
Amrutha NA; Archana PR; Mohan SG; Anto RJ; Sadasivan C
J Cell Biochem; 2019 Oct; 120(10):16643-16657. PubMed ID: 31095793
[TBL] [Abstract][Full Text] [Related]
3. Virtual screening-based identification of novel fatty acid synthase inhibitor and evaluation of its antiproliferative activity in breast cancer cells.
Amrutha Nisthul A; Archana PR; Anto RJ; Sadasivan C
J Mol Graph Model; 2021 Jun; 105():107903. PubMed ID: 33780787
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and anticancer activity of some novel 1H-benzo[d]imidazole-5-carboxamide derivatives as fatty acid synthase inhibitors.
Singh S; Paul S; Brás NF; Kundu CN; Karthikeyan C; Moorthy NSHN
Bioorg Chem; 2023 Sep; 138():106658. PubMed ID: 37331170
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis.
Lee KH; Lee MS; Cha EY; Sul JY; Lee JS; Kim JS; Park JB; Kim JY
Mol Med Rep; 2017 Apr; 15(4):2163-2173. PubMed ID: 28260110
[TBL] [Abstract][Full Text] [Related]
6. Comparative docking of dual conformations in human fatty acid synthase thioesterase domain reveals potential binding cavity for virtual screening of ligands.
John A; Vetrivel U; Subramanian K; Deepa PR
J Biomol Struct Dyn; 2017 May; 35(6):1350-1366. PubMed ID: 27145135
[TBL] [Abstract][Full Text] [Related]
7. Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines.
Hill TK; Davis AL; Wheeler FB; Kelkar SS; Freund EC; Lowther WT; Kridel SJ; Mohs AM
Mol Pharm; 2016 Mar; 13(3):720-8. PubMed ID: 26824142
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
Lupu R; Menendez JA
Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665
[TBL] [Abstract][Full Text] [Related]
9. An Inhibitor of Fatty Acid Synthase Thioesterase Domain with Improved Cytotoxicity against Breast Cancer Cells and Stability in Plasma.
Lupien LE; Dunkley EM; Maloy MJ; Lehner IB; Foisey MG; Ouellette ME; Lewis LD; Pooler DB; Kinlaw WB; Baures PW
J Pharmacol Exp Ther; 2019 Oct; 371(1):171-185. PubMed ID: 31300609
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, Biological Evaluation and Molecular Dynamics Simulation Studies of Novel Diphenyl Ethers.
Khade AB; Kar SS; Alummoottil CT; Tiwari A; Tiwari M; Eshwara VK; Bhat P; Giliyar VB; Shenoy GG
Med Chem; 2020; 16(2):256-270. PubMed ID: 30848207
[TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN).
Martin MW; Lancia DR; Li H; Schiller SER; Toms AV; Wang Z; Bair KW; Castro J; Fessler S; Gotur D; Hubbs SE; Kauffman GS; Kershaw M; Luke GP; McKinnon C; Yao L; Lu W; Millan DS
Bioorg Med Chem Lett; 2019 Apr; 29(8):1001-1006. PubMed ID: 30803804
[TBL] [Abstract][Full Text] [Related]
12. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
Fako VE; Wu X; Pflug B; Liu JY; Zhang JT
J Med Chem; 2015 Jan; 58(2):778-84. PubMed ID: 25513712
[TBL] [Abstract][Full Text] [Related]
13. Progress in the development of fatty acid synthase inhibitors as anticancer targets.
Mullen GE; Yet L
Bioorg Med Chem Lett; 2015 Oct; 25(20):4363-9. PubMed ID: 26364942
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors.
Angeles TS; Hudkins RL
Expert Opin Drug Discov; 2016 Dec; 11(12):1187-1199. PubMed ID: 27701891
[TBL] [Abstract][Full Text] [Related]
15. (-)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer.
Crous-Masó J; Palomeras S; Relat J; Camó C; Martínez-Garza Ú; Planas M; Feliu L; Puig T
Molecules; 2018 May; 23(5):. PubMed ID: 29751678
[TBL] [Abstract][Full Text] [Related]
16. Natural fatty acid synthase inhibitors as potent therapeutic agents for cancers: A review.
Zhang JS; Lei JP; Wei GQ; Chen H; Ma CY; Jiang HZ
Pharm Biol; 2016 Sep; 54(9):1919-25. PubMed ID: 26864638
[TBL] [Abstract][Full Text] [Related]
17. In Silico Structure Prediction of Human Fatty Acid Synthase-Dehydratase: A Plausible Model for Understanding Active Site Interactions.
John A; Umashankar V; Samdani A; Sangeetha M; Krishnakumar S; Deepa PR
Bioinform Biol Insights; 2016; 10():143-54. PubMed ID: 27559295
[TBL] [Abstract][Full Text] [Related]
18. Destabilization of Fatty Acid Synthase by Acetylation Inhibits De Novo Lipogenesis and Tumor Cell Growth.
Lin HP; Cheng ZL; He RY; Song L; Tian MX; Zhou LS; Groh BS; Liu WR; Ji MB; Ding C; Shi YH; Guan KL; Ye D; Xiong Y
Cancer Res; 2016 Dec; 76(23):6924-6936. PubMed ID: 27758890
[TBL] [Abstract][Full Text] [Related]
19. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?
Lupu R; Menendez JA
Endocrinology; 2006 Sep; 147(9):4056-66. PubMed ID: 16809439
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
Goswami S; Sharma-Walia N
Oncotarget; 2016 Sep; 7(37):58953-58974. PubMed ID: 27270654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
